Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme

Stock Information for Qualigen Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Qualigen Therapeutics Inc.

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
Qualigen to participate in next funding round for NanoSynex
Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
Qualigen Therapeutics, Inc. Announces management changes.
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.